Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study

BMC Cardiovascular DisordersBMC series – open, inclusive and trusted201717:26

https://doi.org/10.1186/s12872-016-0456-3

  • Received: 15 October 2016
  • Accepted: 22 December 2016
  • Published:
Open Peer Review reports

Abstract

Background

Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. Multiple genetic variants in combination with various environmental risk factors have been implicated. This study aimed to investigate the association of twelve thrombotic and atherosclerotic gene variants in combination with other environmental risk factors with CAD risk in a preliminary sample of Egyptian CAD patients.

Methods

Twenty three consecutive CAD patients undergoing diagnostic coronary angiography and 34 unrelated controls, have been enrolled in the study. Genotyping was based on polymerase chain reaction and reverse multiplex hybridization. Five genetic association models were tested. Data distribution and variance homogeneity have been checked by Shapiro-Wilk test and Levene test, respectively; then the appropriate comparison test was applied. Spearman’s rank correlation coefficient was used for correlation analysis and logistic regression has been performed to adjust for significant risk factors. Clustering the study participants according to gene-gene and gene-environment interaction has been done by Detrended Correspondence Analysis (DCA).

Results

The univariate analysis indicated that the five variants; rs1800595 (FVR2; factor 5), rs1801133 (MTHFR; 5,10-methylenetetrahydrofolate reductase), rs5918 (HPA-1; human platelet antigen 1), rs1799752 (ACE; angiotensin-converting enzyme), and rs7412 and rs429358 (ApoE; apolipoprotein E) were significantly associated with CAD susceptibility under different genetic models. Multivariate analysis revealed clustering of the study population into three patient groups (P) and one control group. FVR2 was the most variant associated with CAD patients, combined with the factor V Leiden (FVL) variant in P1 cluster and with both ACE and MTHFR 667C > T in P2. Whereas, P3 was mostly affected by both MTHFR 667C > T and FXIII (factor 13) V89L mutations. When combined with traditional risk factors, P1 was mostly affected by dyslipidemia, smoking and hypertension, while P2 was mostly affected by their fasting blood sugar levels and ApoE variant.

Conclusions

Taken together, these preliminary results could have predictive value to be applied in refining a risk profile for our CAD patients, in order to implement early preventive interventions including specific antithrombotic therapy. Further large scale and follow-up studies are highly recommended to confirm the study findings.

Keywords

  • Coronary artery disease
  • Gene variants
  • Gene-disease interactions
  • Polymorphism

Background

Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide [1]. In Egypt it is responsible for 21% of deaths [2] and reported a prevalence of 8.3% [3]. It is one of the complex diseases that are multifactorial or polygenic disorders, caused by multiple genetic variants with low penetrance in combination with various environmental and lifestyle factors [4]. CAD is characterized by long-term atheromatous plaque formation which culminates into atherothrombotic obstructive lesions leading to tissue damage [5]. Atherosclerosis and thrombosis are the two manifestations underlying CAD. It is known that events such as endothelial dysfunction, inflammation, abnormal lipoprotein and homocysteine metabolism, as well as dysfunctional coagulation and fibrinolysis play a key role in the pathogenesis of CAD [6]. In recent years, several genetic variants robustly associated with CAD have been detected by genome-wide association studies (GWAS), mainly in people of European descent [7]. In order to unravel the genetic profile of a sample of the Egyptian CAD patients with respect to these susceptibility loci, twelve variants were analyzed; Additional file 1: Table S1.

Seven polymorphisms associated with thrombotic risk; (i) Factor V (FV): FV Leiden G1691A (R534Q), leads to activated protein C (APC) resistance on the cleavage of factor V and occurs in 20–50% of patients with venous thromboembolism (VTE). It represents one of the most important genetic risk factors for inherited thrombophilia that increases in homozygous state. The contribution of this polymorphism to the pathogenesis of CAD remains controversial [8, 9] (ii) FVR2 haplotype A4070G (H1299R) was found to be in complete linkage disequilibrium with Factor V Leiden and may confer mild APC resistance. When interacting with the Factor V Leiden mutation could produce a more severe APC resistance phenotype and increased the risk for VTE associated with Factor V Leiden by approximately 3-fold [10]. (iii) Prothrombin, (PTH; Factor II) G20210A; the A allele was previously shown to be associated with increased prothrombin levels due to an alteration in the mRNA processing. Its presence with a hypercoagulable state, imply a moderate association with a higher CAD risk [11, 12]. In addition, A allele carriers had about 3-fold elevated risk for cerebral and deep vein thrombosis. This risk increased significantly when combined with FV Leiden [13]. (iv) Factor XIII (FXIII) 163G > T (V34L); most of clinical studies have demonstrated a lower incidence of both venous and arterial thrombosis in carriers of the mutant allele (34Leu) compared to Val/Val carriers [14]. This could be explained by lower plasma level of FXIII in carriers of L34 with increased its activation that result in less stabilized and thinner fibrin clot due to easy dissociation of its 2A and 2B subunits [15] (v) 5,10-Methylenetetrahydrofolate Reductase (MTHFR) C677T and (vi) MTHFR A1298C. The 677TT homozygosity and 677CT/1298 AC compound heterozygote genotypes have been shown to have decreased MTHFR activity and higher predisposition to arterial and venous thrombosis in the presence of additional risk factors [16, 17]. (vii) Plasminogen Activator Inhibitor 1 (PAI-1, Serpin E1) 4G/5G; the 4G allele was previously found to be associated with higher PAI-1 transcription rates and considered to be a mild risk factor for VTE and myocardial infarction (MI) [18].

Other five variants associated with atherosclerosis; (viii) Beta-Fibrinogen (FGB) -455G > A; confers elevated β-fibrinogen plasma levels, which are directly related to increase the risk of acute coronary syndromes (ACS) [19], premature MI [20] and ischemic stroke [21]. However controversial findings of some researchers that show a protective role of this polymorphism against non-fatal acute MI [22] still present. (ix) Human Platelet Antigen 1 (HPA-1; Gp IIIa; integrin b3) L33P (1a/b); studies have shown that, in the normal population, the HPA-1b phenotype results in increased platelet aggregation and fibrinogen binding, thus enhancing the risk of MI [23, 24]. (x) Angiotensin-Converting Enzyme (ACE) 287 bp insertion/deletion (I/D): D allele has been associated with the elevated ACE activity and plasma levels; thereby represents a risk factor for MI in older patients and in smokers [25].)xi) Apolipoprotein B (Apo B) R3500Q, that is considered one of the most common single site mutations in the human ApoB gene; results in mild to severe hypercholesterolaemia and an increased risk for early onset atherosclerosis [26]. (xii) Apolipoprotein E (Apo E) E2/E3/E4; an important predictor of the plasma lipid profile with E2 shows the lowest and E4 shows the highest LDL (low density lipoprotein) and total cholesterol levels; E4 allele was associated with increased susceptibility to early-onset MI, particularly in smokers [27].

Taken together, this study aimed to assess the presence of previously mentioned mutations and polymorphisms in a sample of Egyptian CAD patients and to correlate the co-existence and combination of these variants with the clinical and laboratory risk factors in attempt to be helpful in refining a risk profile for our CAD patients, in order to determine the need for and the intensity of follow-up or to influence decisions about staged implementation of preventive interventions with behavioral or drug therapy.

Methods

Study participants

The current observational case-control study included consecutive 23 unrelated Egyptian stable CAD patients undergoing diagnostic coronary angiography and 34 controls. Patients were recruited from the Cardiology Department, Suez Canal University (SCU) Hospital, Ismailia, Egypt, during the period between October 2015 and February 2016. Diagnosis of CAD was based on detailed history taking via a structured interview, thorough clinical examination, resting electrocardiography and echocardiography, followed by coronary angiography. Patients with congenital heart disease or non-atherosclerotic coronary artery disease were excluded. Unrelated healthy blood donors were included as controls. They had no past history of cardiovascular problems and had a normal resting ECG. They were included irrespective of concomitant risk factors for CAD such as obesity, family history of CAD, hypertension, diabetes mellitus, etc. Selective coronary angiography was not performed for controls following our institutional ethical guidelines that do not permit to apply invasive procedures for controls in research work. The study was conducted in accordance with the guidelines in the Declaration of Helsinki and approved by the Medical Research Ethics Committee of SCU (approval no. 2734). Written informed consent was obtained from all participants.

Cardiovascular disease (CVD) risk assessment

Cardiovascular risk factors were recorded as described previously [28]. Hypertension was defined if the patient was receiving anti-hypertensive drugs or blood pressure exceeded 140/90 mmHg in repeated measurements. Diabetes was considered as a blood sugar ≥ 200 mg/dl on admission, fasting glycemia ≥ 126 mg/dl in two determinants or prior prescription of hypoglycemic drugs. Dyslipidemia was identified if had at least one of the following; triglycerides (TG) ≥ 150 mg/dl, total cholesterol (TC) >200 mg/dl, high density lipoprotein (HDL) <40 mg/dl in males and <50 mg/dl in females or receiving lipid-lowering drugs. Height and weight were measured in all participants and the body mass index (BMI) was calculated. BMI >25 and >30 were considered overweight and obesity, respectively. Individuals who smoked regularly during the previous 12 months were classified as smokers. Other risk factors as lack of exercise and family history of premature CAD (first degree male relatives <55 years or females <65 years) were documented [29].

Multiple methods were used for risk assessment: (1) A qualitative individual risk factor approach in which the sum of risk factors was counted using risk factor categories [30]. (2) A quantitative estimate; “Global CAD risk model” using gender-specific coronary disease prediction algorithm which estimates multivariable CAD risk based on the magnitude or degree of the risk factors [31]. The researchers tried to follow the GRIPS (genetic risk prediction studies) guidelines in reporting the current studied data [32], although our study is not a predictive one, but is considered as a preliminary step in risk assessment in our CAD population.

Echocardiography

A two-dimensional conventional echocardiographic study was performed on all patients using the standard views to exclude the presence of structural heart disease using a commercially available system (General Electric Healthcare Company, Vivid seven Dimensions Vingmed and Horten- Norway) with a 2.5-MHz phased array probe. All echocardiographic data [i.e. the systolic (ejection fraction) and diastolic (grade) functions] were interpreted by two independent experts in echocardiography.

Coronary angiography

Selective coronary cineangiography was performed for all patients using standard, modified Seldinger’s technique [33, 34]. Significant obstructive lesions were diagnosed by visual estimation as the presence of ≥ 50% luminal diameter stenosis in at least one major epicardial coronary artery; left main coronary artery (LMCA), left anterior descending (LAD) coronary artery, right coronary artery (RCA), and circumflex coronary artery (Cx) [35]. Basal angiographic characteristics of patients, such as the location and number of diseased vessels were documented [36]. Multivessel disease (MVD) was defined if ≥ 50% luminal narrowing extended to involve two or three major coronary arteries. Vessel scores ranged from 0 to 3, depending on the number of involved vessels.

A modified Gensini score; a quantitative scoring system applied in our hospital protocols, was used to assess CAD extent and severity from coronary angiograms, taking into account the vessel affected and lesion location, the cumulative effect of multiple lesions, the degree of stenosis, and the influence of collaterals [34, 37]. Each item was assigned a number of points. The score for each vessel was calculated separately, and eventually all are added up to give the total score. The following equation was used: severity score x the segment location multiplying factor x collateral adjustment factor [37]. Scores were determined and interpreted by two independent angiographers who were blinded to the clinical data. A Gensini score value greater than 20 was defined as a high Gensini score [38].

Specimen collection and the laboratory investigations

Five milliliter overnight fasting blood samples were collected on both trisodium EDTA (1 mg/ml) tubes for subsequent genetic analysis study and Serum Separator Vacutainer Tubes II (Becton Dickinson Plymouth). After blood clotting, the latter tubes were centrifuged immediately at 2500 rpm for 20 min and the separated serum were aliquoted into eppendorfs (1 ml per aliquot) and stored at -20 °C for subsequent biochemical assay. Fasting blood glucose (FBG), serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-c) and serum triglycerides (TG) were determined by the enzymatic method using Hitachi 912 automated chemistry analyzer (Roche Diagnostics Co, Mannheim, Germany). Low density lipoprotein-cholesterol (LDL-c) value was calculated by the Friedewald’s equation [39] as all the study serum TG samples were < 400 mg/dl.

DNA extraction and In vitro amplification

DNA was isolated from whole blood within 2 h from collection using ABIOpureTM Total DNA (version 2.0) (AllianceBio, Catalog no. M501DP100) following the protocol supplied by the manufacturer. DNA concentration and purity at the absorbance ratio 260/280 nm were determined by NanoDrop ND-1000 spectrophotometer (NanoDrop Tech., Inc. Wilmington, DE, USA). Amplification was performed using biotinylated ready-made primers enclosed in CVD StripAssay kit (ViennaLab Labordiagnostika GmbH, Vienna, Austria) [40]; Fig. 1. Polymerase chain reaction (PCR) was performed in a 25-μl reaction volume containing 15 μl amplification mix, 5 μl of Taq DNA polymerase (0.2 U/μl) in the Taq dilution buffer, and 200 ng DNA template. It was carried out in a T-Professional Basic, Biometra PCR System (Biometra, Goettingen, Germeny) at 94 °C for 2 min as pre-PCR, then thermocycling at 94 °C for 15 s, 58 °C for 30 s, and 72 °C for 30 s (35 cycles), with subsequent final extension at 72 °C for 3 min and hold at 4 °C. Amplification products were analyzed by gel electrophoresis (2.5% agarose gel). The following fragment lengths were detected: 134, 165, 173, 202, 223, 254, 283, 324 bp.
Fig. 1
Fig. 1

Design of CVD strip assay test used in the current study (Ref 4-240). The left strip represents an example of the genotype results of a case in the current study

Reverse multiplex hybridization

Hybridization of amplification products with saline sodium phosphate EDTA (SSPE) buffer containing 0.5% sodium dodecyl sulfate (SDS) for 30 min was performed to the test strips containing allele-specific oligonucleotide probes immobilized as an array of parallel lines. The strip assays cover 12 variants in the following order: FV 1691G > A (Leiden), FV H1299R (R2), Prothrombin 20210G > A, Factor XIII V34L, β-fibrinogeen -455G > A, PAI-1 4G/5G, HPA1 a/b, MTHFR 677C > T, MTHFR 1298A > C, ACE I/D, Apo B R3500Q, Apo E ε1/ε2/ε3/ε4, Fig. 1. Following hybridization steps, the bounded biotinylated sequences on the strips were washed with prewarmed Stringent Wash Solution A (SSPE buffer containing 0.1% SDS) in a microplate thermo-shaker (PST-60HL, Biosan, Riga, Latvia). Then incubated with a conjugate solution containing streptavidin-alkaline phosphatase at room temperature for 15 min. Repeated washing steps with Wash Solution B containing 0.05% sodium azide (NaN3) was done. Finally color development was performed using color substrates containing nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) in the dark. Genotype interpretation was determined using the enclosed CollectorTM sheet with certain scale. Positive and negative control lines were checked for strip validation; Fig. 1. Positively stained lines were visually noted for each polymorphic position by two independent coauthors and signal pattern of bands were translated into schematic results using stripassay® online calculator [41]; (Additional file 2: Figure S1).

Statistical analysis

Data were managed using the “Statistical Package for the Social Sciences (SPSS) for windows” software (version 20.0) with the aid of Deducer for R-2.15.0 and Microsoft excel 2016. Hardy-Weinberg equilibrium in patients and controls was estimated using the Online Encyclopedia for Genetic Epidemiology (OEGE) software [42]. Pairwise linkage disequilibrium (LD) based on the genotyping data was computed using Haploview software version 4.1. Five genetic association models were used; allelic model, homozygote and heterozygote comparison, dominant and recessive models [43]. Categorical variables were compared using the chi-square (χ2) or Fisher’s exact tests where appropriate, while the Student̕ s t test was used to compare continuous variables between two groups in case the data distribution was concordant with normal distribution (Shapiro-Wilk test) and after checking variance homogeneity (Levene test). If the data did not meet the criteria mentioned above, the non-parametric Mann Whitney-U (MW) and Kruskal-Wallis tests were applied. Spearman’s rank correlation coefficient was used for correlation analysis. A two-tailed p-value of < 0.05 was considered statistically significant. Logistic regression has been performed to adjust for significant risk factors using the backward method. For clustering the study participants according to gene-gene and gene-environment interaction, Detrended Correspondence Analysis (DCA) was implemented in PC-ORD version 5, using the default number of segments 26 and rescaling axes [44].

Results

Baseline characteristics of the study population

The general clinical and biochemical characteristics of the study groups are shown in Table 1. A total of 23 patients (17 men and 6 women) had undergone coronary angiography, while 34 apparently healthy subjects were assigned to the control group. There was no significant difference in the frequency of traditional risk factors of cardiovascular disease between patients and controls (as gender, obesity, family history of CAD, and diabetes mellitus). None of the controls were smokers or hypertensive. However, CAD patients had significantly higher glucose levels and worse lipid profile than controls (p ≤ 0.001). A higher proportion of patients had significantly over three traditional risk factors compared to controls (60.9 and 5.9%, respectively). Coronary angiography revealed that fifth of patients (21.7%) had no occlusion and only 15 out of 23 patients had significant stenosis (≥50% occlusion); 40% (6/15) of whom had complete luminal occlusion. In addition, nearly two-thirds (10/18) of patients with luminal occlusion, had multivessel disease.
Table 1

Clinical and biochemical characteristics of CAD patients and controls

Characteristics

Controls (n = 34)

Patients (n = 23)

p value

OR (95% CI)

Age, mean (y)

54.7 ± 10.1

54.0 ± 10.1

0.810

 

Gender

 Females

16 (47.1)

6 (26.1)

0.166

Reference

 Males

18 (52.9)

17 (73.9)

 

2.51 (0.79–7.94)

BMI, kg/m2

27.7 ± 1.86

28.1 ± 2.07

0.435

 

Obesity

6 (17.6)

5 (21.7)

0.742

1.29 (0.34–4.88)

Smoking

--

13 (56.5)

  

FH CAD

12 (35.3)

6 (26.1)

0.567

0.64 (0.20–2.07)

Hypertension

--

10 (43.5)

  

Diabetes

12 (35.3)

7 (30.4)

0.780

0.82 (0.25–2.49)

Dyslipidemia

--

19 (82.6)

  

Biochemical data

 FBS (mg/dl)

99.4 ± 25.7

145.6 ± 62.2

<0.001

 

 TC (mg/dl)

170 ± 18.4

207 ± 61.5

0.001

 

 TG (mg/dl)

103 ± 33.1

155 ± 54.4

<0.001

 

 LDL-c (mg/dl)

74.9 ± 12.6

147 ± 66.3

<0.001

 

 HDL-c (mg/dl)

48.6 ± 8.3

37.8 ± 11.4

<0.001

 

No of risk factors

  ≤ 3

32 (94.1)

9 (39.1)

<0.001

Reference

  > 3

2 (5.9)

14 (60.9)

 

24.8 (4.75–130)

Premature CAD

--

9 (39.1)

  

Previous events

--

18 (78.3)

  

Stroke

--

1 (4.3)

  

Lesion type

 100% Normal

--

5 (21.7)

  

  < 50% Occlusion

--

3 (13.0)

  

 50- 99% Occlusion

--

9 (39.2)

  

 100% Occlusion

--

6 (26.1)

  

Lesion site

 Single VD

--

8 (34.8)

  

 Two VD

--

4 (17.4)

  

 Three VD

--

6 (26.1)

  

CAD severity

 Gensini score

--

14 (1.5–62)

  

 Vessel score

--

1.0 (0.0–3.0)

  

Echo findings

 Ejection fraction

57.4 ± 7.98

  

 Mild DD

--

20 (87.0)

  

 SWMA

--

9 (39.1)

  

Values are shown as a number (percentage), mean ± standard deviation, or median (quartiles). CAD coronary artery disease; OR (95% CI), Odds ratio (95% confidence interval); FH family history, FBS fasting blood sugar, TC total cholesterol, TG triglycerides, LDL-c low density lipoprotein-cholesterol, HDL-c high density lipoprotein-cholesterol; Risk factors, Age (men ≥ 45 y and women ≥ 55 y), family history of premature coronary artery disease, hypertension, cigarette smoking, diabetes, hypercholesterolemia, low HDL cholesterol <40 mg/dl, hypertriglyceridemia > 200 mg/dl, and obesity; Premature coronary artery disease, <55 years in males and <65 years in females; previous events, previous acute coronary ischemic events; VD vessel disease (defined as luminal narrowing of > 70%); Gensini score to asses disease severity; DD diastolic dysfunction; SWMA, systolic wall motion abnormalities. P value was generated by using Fisher’s exact test, and Student’s t tests. The bold data are statistically significant at p < 0.05

Genotype analysis of thrombotic and atherosclerotic variants

The observed genotype distribution of thrombotic and atherosclerotic genes were in agreement with Hardy-Weinberg equilibrium in both patients and controls (p > 0.05). However, genotype frequencies of MTHFR 667C > T in the CAD group and ACE I/D in the control group deviated significantly from the HWE (p = 0.041 and 0.001, respectively), possibly due to low sample size.

Among the studied genes, both coagulation factor II (rs1799963) and ApoB100 (rs5742904) variants were normal in all patients and controls, thus they were excluded from further analyses. As shown in Tables 2 and 3, the univariate model indicated that the 5 SNPs (1) rs1800595 (FVR), (2) rs1801133 (MTHFR), (3) rs5918 (HPA-1), (4) rs1799752 (ACE), and (5) rs7412 and rs429358 (ApoE) were significantly associated with CAD disease under different genetic association models. The heterozygote genotype of FVR 4070A > G was significantly higher in patients than controls (p = 0.024) with OR (95% CI) of 4.8 (1.2 to 18.3) and 3.8 (1.12–13.5) under heterozygote comparison and allelic models, respectively. The mutant homozygote TT genotype of MTHFR 667C > T also showed higher liability of CAD under homozygote comparison and allelic models. Carriers of the HPA-1 b allele were more frequent among patients (0.26) compared to control group (0.12), (p = 0.048). ACE D/D genotype and D allele were more prevalent in CAD patients with OR showing higher susceptibility to develop CAD. Whereas, ApoE E2 variant showed protection against developing CAD (0.32 in controls compared to 0.13 in patients group, p = 0.004), while E3 and E4 individuals were >3 times more liable to have the disease compared to E2 carriers. The adjusted odds ratio for conventional risk factors (gender, age, BMI, family history of heart disease, diabetes, and obesity) further demonstrated that FVR*AG, HPA-1 b/b, and ACE* DD genotypes are independent risk factors for occurrence of CAD.
Table 2

Genotype and allele frequencies of thrombotic gene variants in the study population

SNP

Genotypes

Controls (n = 34)

Patients (n = 23)

P values

Crude OR (95% CI)

Adjusted OR (95% CI)

FV: Leiden

Normal

32 (94.1)

20 (87.0)

0.384

1.0

1.0

1691G > A

Hetero

2 (5.9)

3 (13.0)

 

2.4 (0.3–15.6)

3.08 (0.3–26.3)

 

p HWE

0.859

0.737

   
 

MAF (A)

0.03

0.07

0.359

0.4 (0.05–3.1)

 

FV: R2

Normal

30 (8 8.2)

14 (60.9)

0.024

1.0

1.0

H1299R

Hetero

4 (11.8)

9 (39.1)

 

4.8 (1.2–18.3)

7.1 (1.49–33.6)

4070A > G

p HWE

0.715

0.243

   
 

MAF (G)

0.06

0.20

0.024

3.8 (1.12–13.5)

 

FII: PTH

Normal

34 (100)

23 (100)

NA

NA

 

20210G > A

p HWE

NA

NA

   

FXIII

Normal

30 (88.2)

17 (73.9)

0.287

1.0

1.0

V34L

Hetero

4 (11.8)

6 (26.1)

 

2.6 (0.6–10.7)

2.29 (0.48–1.5)

 

p HWE

0.715

0.471

   
 

MAF (T)

0.06

0.13

0.185

0.4 (0.09–1.6)

 

MTHFR

Normal

22 (64.7)

12 (52.2)

0.017

1.0

1.0

677C > T

Hetero

12 (35.3)

6 (26.1)

 

0.9 (0.2–3.1)

0.82 (0.21–3.3)

 

Homo

0 (0.0)

5 (21.7)

 

19 (1.0–388)

 
 

Dominant model

12 (35.3)

11 (47.8)

 

1.6 (0.5–4.9)

 
 

p HWE

0.211

0.041

   
 

MAF (T)

0.18

0.35

0.037

2.4 (1.04–5.9)

 

MTHFR

Normal

10 (29.4)

8 (34.8)

0.648

1.0

1.0

1298A > C

Hetero

16 (47.1)

8 (34.8)

 

0.6 (0.1–2.2)

0.87 (0.21–3.6)

 

Homo

8 (23.5)

7 (30.4)

 

1.1 (0.2–4.3)

1.46 (0.33–6.4)

 

Dominant model

24 (70.6)

15 (65.2)

 

0.7 (0.2–2.4)

 
 

p HWE

0.745

0.146

   
 

MAF (C)

0.47

0.48

0.935

0.9 (0.4–2.1)

 

PAI-1

4G/4G

10 (29.4)

7 (30.4)

0.698

1.0

1.0

4G/5G

4G/5G

18 (52.9)

10 (43.5)

 

0.7 (0.2–2.7)

1.15 (0.24–5.3)

 

5G/5G

6 (17.6)

6 (26.1)

 

1.4 (0.3–6.3)

1.36 (0.27–6.8)

 

Dominant model

24 (70.5)

16 (69.6)

 

0.9 (0.3–3.0)

 
 

p HWE

0.667

0.536

   
 

MAF (5G)

0.44

0.48

0.696

0.8 (0.4–1.8)

 

FV coagulation factor 5, PTH Prothrombin, FXIII coagulation factor 13, MTHFR Methylenetetrahydrofolate reductase, PAI-1 plasminogen activator inhibitor-1

Fisher’s Exact and Chi-square tests were used; adjusted by potential confounders (gender, age, BMI, FH, DM, obesity). Bold values indicate statistically significant at p < 0.05

Table 3

Genotype and allele frequencies of atherosclerotic gene variants in the study population

SNP

Genotypes

Controls (n = 34)

Patients (n = 23)

P values

Crude OR (95% CI)

Adjusted OR (95% CI)

FGB

Normal

22 (64.7)

12 (52.2)

0.636

1.0

1.0

-455G > A

Hetero

10 (29.4)

9 (39.1)

 

1.6 (0.5–5.2)

0.28 (0.02–3.1)

 

Homo

2 (5.9)

2 (8.7)

 

1.8 (0.2–14.7)

1.65 (0.1–20.2)

 

Dominant model

12 (35.3)

11 (47.8)

 

1.6 (0.5–4.9)

 
 

p HWE

0.557

0.866

   
 

MAF (A)

0.21

0.28

0.344

1.5 (0.6–3.6)

 

HPA-1

a/a

26 (76.5)

13 (56.5)

0.112

1.0

1.0

a/b

a/b

8 (23.5)

8 (34.8)

 

2.0 (0.6–6.5)

 
 

b/b

0 (0.0)

2 (8.7)

 

9.8 (0.4–21.9)

4.0 (1.4–6.4)

 

Dominant model

8 (23.5)

10 (43.5)

 

2.5 (0.7–7.8)

 
 

p HWE

0.436

0.638

   
 

MAF (b)

0.12

0.26

0.048

2.6 (0.9–7.1)

 

ACE

I/I

6 (17.6)

2 (8.7)

<0.001

1.0

1.0

I/D

I/D

26 (76.5)

9 (39.1)

 

1.0 (0.1–6.1)

2.79 (0.3–29.7)

 

D/D

2 (5.9)

12 (52.2)

 

18 (2.0–161)

88.3 (4.3–179)

 

Dominant model

28 (82.4)

21 (91.3)

 

2.3 (0.4–12.2)

 
 

p HWE

0.001

0.866

   
 

MAF (D)

0.44

0.72

0.003

3.2 (1.4–7.1)

 

ApoB

Normal

34 (100)

23 (100)

NA

NA

 

R3500Q

p HWE

NA

NA

   

ApoE

E2/E2

0 (0.0)

1 (4.3)

0.009

1.0

 

E2/E3/E4

E2/E4

2 (5.9)

1 (4.3)

 

0.2 (0.0–8.8)

 
 

E2/E3

20 (58.8)

3 (13.0)

 

0.05 (0.0–1.6)

 
 

E3/E3

10 (29.4)

15 (65.2)

 

0.4 (0.01–13.2)

 
 

E3/E4

2 (5.9)

3 (13.0)

 

0.4 (0.01–16.8)

 
 

p HWEa

0.060

0.550

   
 

E3

0.61

0.78

0.004

1.0

 
 

E2

0.32

0.13

 

0.08 (0.04–0.18)

 
 

E4 (MAF)

0.06

0.09

 

0.61 (0.2–1.87)

 

FGB fibrinogen beta polypeptide chain, HPA-1 human platelet antigen 1, ACE angiotensin converting enzyme, ApoB Apolipoprotein B-100, ApoE apolipotprotein E, aThe number of degrees of freedom for the chi-square is equal to 3 for three allele systems and 1 for two allele systems. MAF minor allele frequency. Fisher’s Exact and Chi-square tests were used. Adjusted OR by potential confounders (gender, age, BMI, FH, DM, obesity). Bold values indicate statistically significant at p < 0.05

Among the studied genes, four polymorphisms are located on chromosome 1: FVL (rs6025), FVR (rs1800595), MTHFR (rs1801133), and MTHFR (rs1801131). Haplotype analysis showed the presence of two blocks; block 1 included 667C > T and 1298A > C SNPs of MTHFR gene and block 2 involving F5: Leiden 1691G > A and F5: R2 4070A > G. The marker locations and LD block structure of the haplotype blocks are shown in Fig. 2. Our analysis revealed a significant difference in the distribution of GA haplotype in block 2 between cases and controls (p = 0.039), Table 4.
Fig. 2
Fig. 2

Estimated linkage disequilibrium and location of haplotype blocks. LD plots with 1 Kb and 8 Kb between marks are contained within black triangles in the figure, and markers order are outside these triangles. Evidence for LD is shown as different shades (white for low D’ and dark gray for high D’). The haploblocks were identified using a confidence interval algorithm in haploview program version 4.1

Table 4

Haplotype frequencies and genotype combinations of both F5: Leiden 1691G > A with F5: R2 4070A > G, and MTHFR 667C > T with 1298A > C polymorphisms in CAD patients and controls

Haplotypesa

Overall frequency

Controls (n = 34)

Patients (n = 23)

P values

OR (95% CI)

Genotype combination: MTHFR 667C > T/1298A > C

 CC-AA

11 (19.3)

8 (23.5)

3 (13.0)

0.150

Reference

 CT-AA

3 (5.3)

2 (5.9)

1 (4.3)

 

1.3 (0.08–20.7)

 TT-AA

4 (7.0)

0 (0.0)

4 (17.4)

 

21.8 (0.9–523)

 CC-AC

9 (15.8)

6 (17.6)

3 (13)

 

1.3 (0.19–9.08)

 CT-AC

14 (24.6)

10 (29.4)

4 (17.4)

 

1.06 (0.18–6.2)

 TT–AC

1 (1.8)

0 (0.0)

1 (4.3)

 

7.2 (0.23–225)

 CC-CC

14 (24.6)

8 (23.5)

6 (26.1)

 

2.0 (0.3–10.9)

 CT-CC

1 (1.8)

0 (0.0)

1 (4.3)

 

7.2 (0.23–225)

Genotype combination: FVL 1691G > A/FVR 4070A > G

 GG-AA

41 (71.9)

28 (82.4)

13 (56.5)

0.080

Reference

 GG-AG

11 (19.3)

4 (11.8)

7 (30.4)

 

3.7 (0.9–15.18)

 GA–AA

3 (5.3)

2 (5.9)

1 (4.3)

 

1.07 (0.08–12.9)

 GA-AG

2 (3.5)

0 (0.0)

2 (8.7)

 

10.5 (0.47–235)

Block 1: MTHFR 667C > T/1298A > C

 CC

0.446

45.9

42.8

0.7437

 

 CA

0.308

36.5

22.4

0.1114

 

 TA

0.218

16.5

29.8

0.0926

 

 TC

0.027

1.1

5

0.2134

 

Block 2: FVL 1691G > A/FVR 4070A > G

 GA

0.856

91.2

77.4

0.0397

 

 GG

0.1

5.9

16.1

0.075

 

 AA

0.03

2.9

3

0.9767

 

 AG

0.014

0

3.5

0.121

 

MTHFR, Methylenetetrahydrofolate reductase; FV, coagulation factor 5

aHaploview version 4.1 was used for data analysis. Bold values indicate statistically significant at p < 0.05

Interaction of both gene variants and traditional risk factors with disease risk

Genotype frequencies of variants in patients and controls stratified by cardiovascular risk factors are illustrated in Additional file 1: Tables S2 and S3. Significant difference of frequencies of SNPs was observed with gender, obesity and diabetes. Multivariate analysis using an ordination method was used for data clustering, Fig. 3. Analysis of the whole gene variants showed a tendency of the studied population to cluster into 4 groups; one control and three patient groups. Among patients’ clusters, FVR was the most effective associated gene variant in most of our CAD patients, combined with the FVL variant in P1 cluster and with both ACE and MTHFR 667C > T in P2 cluster. Whereas, the third patient group (P3) was mostly affected by both MTHFR 667C > T and F13 V89L mutations, Fig. 3a. With the intersection of genes with confounders and traditional risk factors, more discrimination between patients and controls was revealed in Fig. 3b. HDL and family history were the most prominent factors in the control group. Patients were clustered into two groups showing more effect of traditional risk factors than genes; P1 group was mostly affected by dyslipidemia, LDL, total triglyceride, total cholesterol, smoking, and hypertension, with little contributing effect of gene variants (HPA-1, ACE, ApoE, and MTHFR1), while P2 cluster was mostly affected by their fasting blood sugar levels and ApoE variant.
Fig. 3
Fig. 3

Detrended correspondence analysis ordination plots showing the distribution of patient and control samples. DCA was done to show the relations among subject groups and genes (a) along with other environmental risk factors (b). DCA was done after rescaling axes. Red circle surrounds a control group while other colored circles for patient groups. Results were plotted on Axes 1 and 2

Correlation analysis between gene variants and risk factors supported the association between these genes and lipid profile, Additional file 1: Table S4. Four thrombotic and four atherosclerotic gene variants were significantly associated with dyslipidemia and lipid profile; FVR (4070A > G) with higher total triglyceride (p = 0.004) and lower HDL (p = 0.030), F13A1 (V35L) and HPA-1 (a/b) with higher LDL (p = 0.047 and 0.024, respectively), MTHFR (667C > T) with total cholesterol (p = 0.004), and ApoE with triglyceride (p = 0.002) and LDL (p = 0.017). In addition, similar to DCA plot results, ApoE was also positively correlated with fasting blood sugar levels (r = 0.267, p = 0.044). However, HPA-1 (a/b) variant showed significant association with patients’ age (r = -0.352, p = 0.007); youngest age (35.5 ± 10.6) in mutant homozygote individuals, intermediate age (51.3 ± 9.5) in heterozygotes, and later age at onset (56.7 ± 9.0) in normal homozygote carriers (p = 0.016).

Association of traditional risk factors with disease phenotype

Multivessel disease was more frequent among males (p = 0.043) and smokers (p = 0.020). Males also had a higher gensini score (p = 0.048) with OR (95% CI) of 15 (1.2–18.5). CAD patients who had experienced previous acute coronary ischemic events were two times more likely to have significant occlusion >50% (p = 0.033). No association was observed between other traditional risk factors and the degree of CAD at coronary angiography, Table 5. In addition, none of the risk factors showed association with any other clinical characteristics as premature CAD, previous acute coronary ischemic events, echocardiography findings (ejection fraction, diastolic dysfunction, and systolic wall motion abnormalities) in CAD patients (data not shown).
Table 5

Association between traditional risk factors and clinical characteristics of CAD patients

Risk factor

Gensini score

P value

Occlusion

P value

No of BVs

P value

Low

High

<50%

≥50%

SVD

MVD

Number

14

9

8

15

8

10

Gender

 Females

6 (42.9)

0 (0.0)

0.048

2 (25.0)

4 (26.7)

1.00

5 (62.5)

1 (10)

0.043

 Males

8 (57.1)

9 (100)

 

6 (75.0)

11 (73.3)

 

3 (37.5)

9 (90)

 

Obesity

2 (14.3)

3 (33.3)

0.343

0 (0.0)

5 (33.3)

0.122

2 (25)

3 (30)

1.00

Smoking

6 (42.9)

7 (77.8)

0.197

4 (509

9 (60.0)

0.685

2 (25)

8 (80)

0.020

FH CAD

2 (14.3)

4 (44.4)

0.162

2 (25.0)

4 (26.7)

1.00

1 (12.5)

4 (40)

0.314

Hypertension

7 (50.0)

3 (33.3)

0.669

3 (37.5)

7 (46.7)

1.00

5 (62.5)

4 (40)

0.637

Diabetes

4 (28.6)

3 (33.3)

1.00

2 (25.0)

5 (33.3)

1.00

3 (37.5)

3 (30)

1.00

Dyslipidemia

11 (79)

8 (88.9)

1.00

6 (75.0)

13 (86.7)

0.589

5 (62.5)

9 (90)

0.275

Premature CAD

5 (35.7)

4 (44.4)

1.00

3 (37.5)

6 (40)

1.00

3 (37.5)

4 (40)

1.00

Previous events

9 (64.3)

9 (100)

0.116

4 (50.0)

14 (93.3)

0.033

7 (87.5)

9 (90)

1.00

Data are presented as number (percentage). CAD coronary artery disease, FH family history; premature coronary artery disease, <55 years in males and <65 years in females; previous events, previous acute coronary ischemic events, No of BVs number of blood vessels, SVD single vessel disease, MVD multivessel disease. Fisher’s exact test was used. Bold values indicate statistically significant at p < 0.05

Association of gene variants with disease phenotype

As shown in Table 6, CAD patients carrying mutant allele of FVR polymorphism had a lower genseni score (p = 0.04) with OR (95% CI) of 0.09 (0.009–0.96) (r = -0.460, p = 0.027), and lower risk of significant occlusion ≥ 50% (p = 0.023) with OR (95% CI) of 0.08 (0.01–0.64) (r = -0.536, p = 0008). In addition, MTHFR 1298A > C mutant homozygotes had a better genseni score (p = 0.035).
Table 6

Association between SNP genotypes and clinical characteristics of CAD patients

Gene SNP

G

Gensini score

P value

Occlusion

P value

No of BVs

P value

Low

High

<50%

≥50%

SVD

MVD

Number

14

9

8

15

8

10

FVL

N

11 (78.6)

9 (100)

0.253

7 (87.5)

13 (86.7)

1.00

7 (87.5)

9 (90)

1.00

H

3 (21.4)

0 (0.0)

1 (12.5)

2 (13.3)

 

1 (12.5)

1 (10)

FVR

N

6 (42.9)

8 (88.9)

0.040

2 (25)

12 (80)

0.023

4 (50)

9 (90)

0.118

H

8 (57.1)

1 (11.1)

6 (75)

3 (20)

4 (50)

1 (10)

F13A1

N

12 (85.7)

5 (55.6)

0.162

6 (75)

11 (73.3)

1.00

7 (87.5)

6 (60)

0.314

H

2 (14.3)

4 (44.4)

2 (25)

4 (26.7)

1 (12.5)

4 (40)

MTHFR 1

N

8 (57.1)

4 (44.4)

0.558

4 (50)

8 (53.3)

0.962

6 (75)

5 (50)

0.234

H

4 (28.6)

2 (22.2)

2 (25)

4 (26.7)

2 (25)

2 (20)

M

2 (14.3)

3 (33.3)

2 (25)

3 (20)

0 (0.0)

3 (30)

MTHFR 2

N

4 (28.6)

4 (44.4)

0.035

4 (50)

4 (26.7)

0.250

2 (25)

4 (40)

0.167

H

3 (21.5)

5 (55.6)

1 (12.5)

7 (46.7)

2 (25)

5 (50)

M

7 (50)

0 (0.0)

3 (37.5)

4 (26.7)

4 (50)

1 (10)

PAI-1

N

5 (35.7)

2 (22.2)

0.730

2 (25)

5 (33.3)

0.660

3 (37.5)

3 (30)

0.869

H

6 (42.9)

4 (44.4)

3 (37.5)

7 (46.7)

3 (37.5)

5 (50)

M

3 (21.4)

3 (33.3)

3 (37.5)

3 (20)

2 (25)

2 (20)

FGB

N

7 (50)

5 (55.6)

0.490

3 (37.5)

9 (60)

0.583

5 (62.5)

5 (50)

0.799

H

5 (35.7)

4 (44.4)

4 (50)

5 (33.3)

2 (25)

4 (40)

M

2 (14.3)

0 (0.0)

1 (12.5)

1 (6.7)

1 (12.5)

1 (10)

HPA-1

N

7 (50)

6 (66.7)

0.595

4 (50)

9 (60)

0.851

6 (75)

6 (60)

0.610

H

6 (42.9)

2 (66.7)

3 (37.5)

5 (33.3)

2 (25)

3 (30)

M

1 (7.1)

1 (22.2)

1 (12.5)

1 (6.7)

0 (0.0)

1 (10)

ACE

N

1 (7.1)

1 (11.1)

0.829

1 (12.5)

1 (6.7)

0.894

0 (0.0)

1 (10)

0.287

H

5 (35.7)

4 (44.4)

3 (37.5)

6 (40)

2 (25)

5 (50)

N

8

4 (44.4)

4 (50)

8 (53.3)

6 (75)

4 (40)

ApoE

2/2

0 (0.0)

1 (11.1)

0.492

0 (0.0)

1 (6.7)

0.658

0 (0.0)

1 (10)

0.834

2/3

2 (14.3)

1 (11.1)

1 (12.5)

2 (13.3)

1 (12.5)

1 (10)

2/4

1

0 (0.0)

1 (12.5)

0 (0.0)

0 (0.0)

0 (0.0)

3/3

10

5 (55.6)

5 (62.5)

10 (66.6)

6 (75)

7 (70)

3/4

1

2 (66.7)

1 (12.5)

2 (13.3)

1 (12.5)

1 (10)

Data are presented as number (percentage). CAD coronary artery disease, SNP single nucleotide polymorphism, G genotype, N normal, H heterozygote, M mutant, No of BVs number of blood vessels, SVD single vessel disease, MVD multivessel disease, FV coagulation factor 5, MTHFR 1 and 2 Methylenetetrahydrofolate reductase (rs1801133) and (rs1801131), respectively, PAI-1 plasminogen activator inhibitor-1, FGB fibrinogen beta polypeptide chain, HPA-1 human platelet antigen 1, ACE angiotensin converting enzyme, ApoE apolipotprotein E. Fisher’s exact test was used. Bold values indicate statistically significant at p < 0.05. PTH (Prothrombin) and ApoB (Apolipoprotein B-100) gene variants were excluded from analysis as all patients were normal

Association analysis of gene variants with other clinical characteristics and echocardiography parameters showed FVR polymorphism to be inversely related to systolic wall motion abnormalities (r = -0.416, p = 0.048) and F13A1 (V35L) SNP to be associated with lower ejection fraction in heterozygote compared to normal homozygote (p = 0.020) with moderate inverse correlation (r = -0.50, p = 0.015) (data not shown).

Discussion

To our knowledge, this is the first study conducted to investigate the interaction between twelve atherosclerosis and thrombosis related gene variants and the environmental risk factors that could increase the susceptibility to coronary artery disease in Egyptian CAD patients. The previous studies have confirmed that understanding the gene–environment interactions is very important for the development of novel preventive and therapeutic approaches to reduce the risk of CAD [4547].

In the current study FVR was the most variant associated with CAD patients, combined with the FVL variant to increase CAD risk in one of the patient clusters and with both ACE and MTHFR 667C > T in the second cluster. Because CAD is a multifactorial disorder, its genetic components may be a combined effect of a number of genes with each playing only a small role. Butt et al. [48] have reported that the predisposition imparted by individual genes may act independently or interact with other genes to result in an additive effect or a synergistic coeffect. The FV:R2 A4070G variant causes amino acid replacement of histidine for arginine at the codon 1299 in the FV B domain. This polymorphism, which marked by the HR2 haplotype was reported to affect the plasma level of FV and contribute to the APC resistance [49]. Although the homo mutant genotype was absent in CAD patients and controls in the current work, this variant confers high susceptibility to CAD risk under the heterozygous and allelic models. Segers et al. [50] suggested that the reduced level of expression of FV: R2 is the most likely explanation for the enhanced thrombophilic phenotype in R2 carriers. Although there are no conclusive data available that associate the R2 haplotype per se with a relevant increased risk of thrombosis (i.e. taken in consideration that FV: Leiden frequency was comparable between CAD patient and control groups in the current study), it was observed previously that male carriers of the FV: R2 polymorphism, have increased circulating levels of FVIII [51]. Although there was no biochemical explanation has been given for this observation, it has been speculated that altered FV anticoagulant activity of FV: R2 results in diminished the proteolytic control of FVIII levels by the protein C pathway [50]. Since increased levels of FVIII are an independent risk factor for the occurrence of venous thrombosis, this may explain the potential association between FV: R2 and thrombosis. Nevertheless, we found that patients carrying the G allele unexpectedly displayed a mild phenotype (i.e. lower Genseni score and lower number of MVD) than wild-type genotype carriers. It seems therefore that the HR2 haplotype in our population preferentially increases the CAD susceptibility but correlates with mild disease severity. It should be kept in mind, however, that thrombosis is a multifactorial disease in which genetic and acquired risk factors interact dynamically. Therefore, the role that FV plays in the etiology of thrombosis is largely dependent on other factors that influence the impact of any altered FV phenotype [50] and the disease outcome depends on the sum of other multiple interacting factors determine the severity of the disease. This finding should be validated in future larger scale studies to be conclusive.

The mutant homozygote TT genotype of MTHFR 667C > T (rs1801133) was found to be more frequent among the studied CAD Egyptian patients (21.7%) and was not found in the controls. This variant showed significantly higher susceptibility for CAD under homozygote and allelic models and it was one of the most effective associated gene variants in combination with other variants for clustering our CAD patients by multivariate analysis (i.e. the combined occurrence of the MTHFR 677TT, ACE DD and FVR 4070AG genotypes seems to magnify the CAD risk in our population). MTHFR gene is located on chromosome 1p36.3 and contains more than hundred SNPs, the most studied variants are rs1801133 and rs1801131 that included in the current study. The 667C > T transition in exon 5 of the first SNP is resulting in a change of alanine to valine (A222V) near the FAD (flavin-adenine-dinucleotide) cofactor binding region, and the other variant caused by the point mutation of A to C at nucleotide 1298 of coding sequence leads to substitution of glutamine by alanine at the amino acid number 470 in the protein structure [52]. In silico tools predicted the former variant (i.e. 667C > T) in exon 5 to be deleterious in contrast to the later neutral one. This could explain why MTHFR 667C > T; was associated with CAD risk in our population as the enzyme with valine was shown previously to be associated with increased thermoliability and reduced enzymatic activity to about 30% if mutant homozygous and 65% if heterozygous [53]. This reduced activity resulting in hyperhomocysteinemia when folate status is low that has been linked to thrombosis and considered as a major independent risk factor for cardiovascular diseases [54]. Similar to our results, when Almawi et al. [55] studied FV 1691 G > A, PT 20210 G > A, and MTHFR 677 C > T gene variants in angiographically documented CAD, they found a strong association of hyperhomocysteinemia and homozygosity of the MTHFR 677 C > T, but not FV: Leiden or PT 20210 G > A mutations with CAD. The results of the present study are also in agreement with Neto et al. [56] who found the MTHFR 677 T/T genotype to predispose to premature atherosclerotic coronary artery disease, and with Yamada et al. [57] and Schürks et al. [58] who reported increased risk for MI and ischemic stroke, respectively. Otherwise, our findings were in contrast to Hsu et al. [59], Yilmaz et al. [60] and Caner et al. [61] who reported that the MTHFR C677T mutation was not associated with the risk of CAD or venous thrombosis among Chinese in Taiwan nor among Turkish patients, respectively. These contradictory results between different studies could be attributed to relatively small sample size, low frequency of gene variants and ethnic heterogeneity [50].

The plasminogen activator inhibitor-1 (PAI-1) is a 52 kDa glycoprotein encoded by the serine protease inhibitor (SERPINE1) gene [62]. It is secreted by endothelial cells and is stored and released from the platelets during activation to downregulate the fibrinolysis process by inhibiting plasminogen to plasmin conversion induced by either tissue-plasminogen activator or urokinase [63]. The current study functional insertion/deletion promoter variant at -675 position (rs1799889), has been associated with increased risk of atherosclerosis and thrombosis previously with inconsistent results [20, 6467]. As both the -675 4G and 5G alleles have a binding site for a common transcription activator and the 5G allele has an additional binding site for a repressor, this leads to 5G allele is slightly less transcriptionally active than the 4G and subsequently is associated with lower PAI-1 plasma levels and lower risk of thrombus stabilization [68]. Our results showed no association between PA1 4G/5G and the studied sample of CAD patients. This is in line with a previous study on Egyptian population [69] and others [20, 65, 70, 71] that also showed lack of association of this risk variant with MI or CAD. A number of evidences could elucidate our findings; first, the pathogenesis of CAD is complex and multifactorial with multiple interacting environmental and genetic determinants; hence PAI-1 is influenced not only by the gene SNP, but also by environmental factors, such as blood sugar, insulin and triglyceride concentrations among others [66]. Considering this fact, in subgroup stratified analysis, the 4G/4G genotype has been shown to be associated with obesity under the dominant genetic model to be in concordance with Mertens et al. [72], who found increased PAI-1 levels are associated with increased visceral obesity due to its production by ectopic fat depots [73]. In addition, Fernandes and Sandrim [74], found that obese women with 4G/4G genotypes were at increased risk of thrombotic diseases. The 5G/5G genotype in our cases has shown to be protective in patients with positive family history for CAD, to be in line with Margaglione et al. [75]. Second, variability in plasma concentrations of PAI-1 has been reported in different ethnic groups worldwide. The 4G/5G variant has been shown to be the predominant effector in some cases [7678], while in others environmental factors such as smoking are involved [79].

Human platelet antigens (HPA), platelet surface receptors, play a key role in the adhesion, activation, and aggregation of platelets. They are formed of two glycoprotein (GP) subunits (GPIIb/IIIa) [80]. The GPIIIa subunit is polymorphic [81]. One of the most studied GPIIIa variant, HPA-1 a/b (c.176 T > C; Lys59Pro), also known as PIA1/A2, has been suggested as an important genetic key player in the CAD pathogenesis [82]. In the current study, our data demonstrated an association between HPA-1 a/b polymorphism and the occurrence of CAD. We found a significant higher prevalence of HPA-1 a/b and HPA b/b genotypes among CAD patients compared to controls. This was consistent with the studies of Weiss et al. [83] and Abboud et al. [84] which reported a strong association between the HPA-1 b allele and genotypes and the risk of CAD. The mutant allele encodes proline instead of lysine at an amino acid position located near the ligand binding site [81]. Bennet et al. [85] showed no impact on ligand binding using static model system. Similarly, our in silico analysis demonstrated L59P mutation to be benign and tolerated. However, in vitro cell culture showed enhanced binding of both fibrinogen and von Willebrand factor (vWF) to the receptor. In the normal population, the HPA-1b phenotype results in increased platelet aggregation and increased fibrinogen binding, thus conferred an increased risk of MI [23, 86], especially in early onset heart disease [83], ischemic stroke [87] and resistance to aspirin [88]. In contrast, other studies reported the absence of any association between the HPA-1a/b missense mutation and the occurrence of coronary diseases [8992]. This discrepancy could be explained by the finding of Zotz et al. [93] who reported that HPA-1 a/b is a risk determinant in patients with already existing atheromatous burden, but not for the development of atheromata.

One of the most popular genetic risk factors in CAD is the ACE insertion/deletion (rs1799752) polymorphism [94]. The ACE gene is located on chromosome 17q23.3 with 26 exons and 25 introns spreading over about 2 Kb [95]. The presence (insertion) or absence (deletion) of an Alu repetitive element (287-bp repeat sequence) in intron 16 results in I and D alleles, respectively [92]. This common polymorphism accounts for 47% of variations within ACE gene [94]. The results of the current study showed that DD genotype could be a considerable risk factor for CAD susceptibility, particularly in females. There was an increased frequency of D allele in CAD patients (0.72) compared to controls (0.44). No association of the gene was observed with other cardiovascular risk factors highlighting more strong effect of ACE with CAD. In 1992, Cambien and his colleagues reported the earliest significant relationship between the DD homozygosity and the risk of CAD [96], and that was followed by the study of Morris et al. [97] who suggested that the DD genotype represents a robust risk factor for MI and sudden death compared to II genotype. In addition, DD genotype was associated with coronary artery spasm that is considered one of the mechanisms of MI [98] and increased risk of restenosis with atherosclerotic lesions after percutaneous transluminal angioplasty [99]. Similar findings were further reported in two meta-analysis studies conducted by Samani et al. [100] and Zhou et al. [101]. Furthermore, numerous studies implicated the DD homozygosity as a key risk factor in other cardiovascular diseases, including hypertension [102], coronary and carotid atherosclerosis [103], cardiomyopathy [104], peripheral arterial disease [105], ischemic stroke [106], and recurrent venous thromboembolism [107]. In contrast, Lindpaintner et al. [108] did not confirm the association between D variant and increased risk of CAD in a large population of American males, and this finding was consistent with that of ours as stratification analysis by gender revealed significant association among females only. ACE, the key regulator in the renin angiotensin system (RAS), has two main physiological functions; converts angiotensin I into a physiologically active peptide angiotensin II (Ang II) and degrades bradykinin, a potent vasodilator [105]. Ang II is the atherogenic component of RAS that increases vascular permeability, stimulates proliferation and migration of vascular smooth muscle cells, induces the expression of inflammatory mediators, and enhances the deposition of extracellular matrix [109]. Reduced bradykinin by ACE decreased endothelium-dependent vasodilators nitric oxide and prostacyclin thus controls blood pressure [103]. The circulatory ACE level is genetically determined by the I/D variant [105]. Individuals with DD genotype have a twofold increase in the serum ACE concentration in the normal population, with ID subjects having intermediate levels [110], leading to higher levels of circulating Ang II and vasoconstriction which are common in MI and hypertensive patients [95]. The results of these studies correlate with those of Suehiro et al. [111] which showed an association between D allele and higher expression of the ACE mRNA that may affect the renin-angiotensin system in local regions. The mechanisms underlying this variation in levels of circulating enzymes by the absence of the Alu repeat sequence within the intron in DD genotype still need to be elucidated.

Two apolipoprotein variants were examined in our study; ApoB-100 R3500Q mutation and ApoE (rs7412 and rs429358). ApoB is the primary apolipoprotein of chyomicrons, VLDL and LDL, which is responsible for carrying fat molecules throughout the body to all tissue cells. The ApoB on the LDL particle acts as a ligand for LDL receptors. High levels of ApoB are the primary drivers of atheroma formation [112]. It is well established that ApoB100 levels are associated with coronary heart disease [113, 114]. Mutations in ApoB gene can cause familial hypercholesterolemia [115]. The R3500Q (rs5742904) mutation in ApoB was found to be a major determinant of LDL levels and coronary artery calcification in the Amish population [112]. Substitution of Arginine with Glutamine is believed to prevent proper folding of ApoB and thereby reducing the ability of LDL particle to bind to the LDL receptor [116]. R3500Q mutation was absent in our study population, possible due to low sample size or ethnic variations. This was consistent with population-based surveys which reported low frequency of R3500Q mutation in non-Amish population [117]. The ApoB gene mutations were not detected in Lebanon [118], Russia [119], Iran [26], and Turkey [120].

The other studied apolipoprotein ApoE is found in chylomicrons and intermediate density lipoprotein (IDL) that is essential for the normal catabolism of triglyceride-rich lipoprotein constituents and cholesterol metabolism [121]. The ApoE gene, mapped on chromosome 19q13.32 in a cluster with ApoC1 and ApoC2, is highly polymorphic [122], with 3 major alleles according to the amino acids at positions 130 (rs429358; c.388 T > C) and 176 (rs7412; c.526C > T) in exon 4: ApoE2 (cys130/cys176), ApoE3 (cys130/arg176), and ApoE4 (arg130/arg176) (ensemble.org). The ApoE polymorphisms were found to affect mRNA transcription and result in increased plasma cholesterol and triglyceride with impaired clearance of lipids from the bloodstream [121]. Moreover, knockout mice lacking ApoE developed extreme hypercholesterolemia after a high-fat diet [123]. In the present study, E3 (rs429358*T, rs7412*C) was the predominant form of gene in both patients and controls followed by E2 variant (rs429358*T, rs7412*T) among the study population, E2 carriers showed protection against developing CAD compared to E3 and E4. Both E3/E3 and E3/E4 genotypes had higher disease risk more than three times when compared to E2 genotypes. ApoE variants were also significantly associated with abnormal triglyceride and LDL-c among our CAD patients. Similar to our findings, E3 isoform was the most frequent ApoE variant in several populations, including Americans [124], Indians [125], Turkish [126], and Saudians [127], thus is considered the wild type ApoE genotype. The presence of E4 isoform (rs429358*C, rs7412*C) was previously associated with increased risk of CAD and mortality [128], atherosclerosis [129], and ischemic cerebrovascular disease [130]. Further meta-analyses studies showed ApoE2 allele to be protective while E4 allele rendered higher susceptibility to heart diseases [119, 131133]. Although these allelic forms differ from each other by only one or two amino acids at 2 sites, these differences alter the ApoE protein structure and function, and thereby have significant physiological consequences [134]. E2 variant with 2 cystienes binds poorly to LDL cell surface receptor compared to E3 and E4, thus can increase the LDLR number, and lowering cholesterol level [122]. On the other hand, E4 isoform with two arginine amino acids exhibits enhanced transfer from HDL to TG-rich lipoproteins, promoting hepatic remnant clearance by ApoE receptors and decreasing LDLR, thereby increasing circulating cholesterol levels [122]. The same variant has also been associated with increased calcium ion levels and apoptosis following mechanical injury [135].

Conclusions

With the caveat that our sample size for this analysis was low, and the current analyses are likely to have been underpowered, our study confirms that CAD development requires more complex interactions among several risk factors [89], including genetic and environmental one. More specifically, it has been found that five variants; rs1800595 (FVR), rs1801133 (MTHFR), rs5918 (HPA-1), rs1799752 (ACE), and rs7412 and rs429358 (ApoE) were significantly associated with CAD susceptibility under different genetic models in the current sample of Egyptian CAD patients. These variants interacted with different traditional risk factors to cluster the current study population into the patient and control subgroups by multivariate analysis application. However, there are some limitations in our study should be considered. First, the study is cross-sectional for the point of the coronary disease investigation and all the study participants were stable CAD patients. Thus, the clinical phenotype was determined up to the time that the study was performed thereby allowing us to detect an association, but not to predict the outcome. Hence, follow-up studies are highly recommended to estimate the effect of the study risk factors on the disease outcome. In addition, including CAD patients with different clinical presentations are recommended to be useful to differentiate the distribution of the genetic pattern analyzed. Second, it is possible that some of our control subjects could have subclinical atherosclerosis that might result in an underestimation of the true risk associated with certain alleles. Additional studies examining coronary angiography free controls, will be of even greater value to more clearly establish the magnitude of risk imparted by the presence of these genetic risk factors. Third, the lack of an association between some variants and CAD may be due to the relatively small sample size that warrant a larger cohort in the same population and in different ethnicity populations to validate the current results.

Abbreviations

ACE: 

Angiotensin-converting enzyme

APC: 

Activated protein C

Apo B: 

Apolipoprotein B

BMI: 

Body mass index

CAD: 

Coronary artery disease

CVD: 

Cardiovascular disease

Cx: 

Circumflex coronary artery

DCA: 

Detrended correspondence analysis

FBG: 

Fasting blood glucose

FGB: 

Beta-fibrinogen

FV (L): 

Factor V Leiden

FXIII: 

Factor 13

HDL: 

High density lipoprotein

HPA-1: 

Human platelet antigen 1

LAD: 

Left anterior descending

LDL: 

Low density lipoprotein

LMCA: 

Left main coronary artery

MTHFR: 

5,10-Methylenetetrahydrofolate Reductase

MVD: 

Multivessel disease

PAI-1: 

Plasminogen activator inhibitor 1

PTH: 

Prothrombin

RCA: 

Right coronary artery

SDS: 

Sodium dodecyl sulfate

TC: 

Total cholesterol

TG: 

Triglycerides

Declarations

Acknowledgements

The authors thank the Oncology Diagnostic Unit and the Center of Excellence, Suez Canal University, Ismailia, Egypt for providing the facilities for performing the research work and thank the patients who agree to participate in the current study.

Funding

No sources of funding were used for this work.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its Additional files 1 and 2.

Authors’ contributions

MSF, EAT, NMA, AF-E and DIB conceived and designed the experiments, MHH recruited the study samples and clinical patient data, EAT, MSF, NMA, AF-E and DIB contributed parts of the experiments, EAT contributed to the statistical analysis. All authors contributed the reagents and materials needed for the current work, and all authors contributed in writing, reading and approval of the final manuscript.

Competing interest

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study was conducted in accordance with the guidelines in the Declaration of Helsinki and it has been approved by the Medical Research Ethics Committee of Faculty of Medicine, Suez Canal University (Approval no. 2734). Written informed consent was obtained from all participants.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Medical Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
(2)
Department of Histology and Cell Biology (Genetics Unit), Faculty of Medicine, Suez Canal University, Ismailia, Egypt
(3)
Clinical Pathology Department, Faculty of Medicine, Sohag University, Sohag, Egypt
(4)
Pulmonologist, Ministry of Health, Cairo, Egypt

References

  1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics-2014 update: a report from the American heart association. Circulation. 2014;129:399–410.PubMedView ArticleGoogle Scholar
  2. Seef S, Jeppsson A, Stafström M. What is killing? People’s knowledge about coronary heart disease, attitude towards prevention and main risk reduction barriers in Ismailia, Egypt (descriptive cross-sectional study). Pan Afr Med J. 2013;15:137.PubMedPubMed CentralGoogle Scholar
  3. Almahmeed W, Arnaout MS, Chettaoui R, Ibrahim M, Kurdi MI, Taher MA, et al. Coronary artery disease in Africa and the Middle East. Ther Clin Risk Manag. 2012;8:65–72.PubMedPubMed CentralView ArticleGoogle Scholar
  4. Liu L, Li Y, Tollefsbol TO. Gene-environment interactions and epigenetic basis of human diseases. Curr Issues Mol Biol. 2008;10:25–36.PubMedPubMed CentralGoogle Scholar
  5. Raposo M, Sousa P, Nemeth S, Couto A, Santos M, Pinheiro J, et al. Polymorphism in cardiovascular diseases (CVD) susceptibility loci in the azores islands (Portugal). Open J Genet. 2011;1:48–53.View ArticleGoogle Scholar
  6. Roy H, Bhardwaj S, Yla-Herttuala S. Molecular genetics of atherosclerosis. Hum Genet. 2009;125:467–91.PubMedView ArticleGoogle Scholar
  7. Bustamante CD, Burchard EG, De la Vega FM. Genomics for the world. Nature. 2011;475:163–5.PubMedPubMed CentralView ArticleGoogle Scholar
  8. Himabindu G, Rajasekhar D, Latheef K, Sarma PVGK, Vanajakshamma V, Chaudhury A, et al. Factor V Leiden mutation is not a predisposing factor for acute coronary syndromes. Indian Heart J. 2012;64:570–5.PubMedPubMed CentralView ArticleGoogle Scholar
  9. Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R. Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes. Thromb Res. 2013;132:151–7.PubMedView ArticleGoogle Scholar
  10. Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011;13:1–16.PubMedView ArticleGoogle Scholar
  11. Burzotta F, Leone AM, Paciaroni K, De Stefano V, Rossi E, Testa L, et al. G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome. Haematologica. 2004;89:1134–8.PubMedGoogle Scholar
  12. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and controls. Lancet. 2006;367:651–8.PubMedView ArticleGoogle Scholar
  13. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–703.PubMedGoogle Scholar
  14. Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys Chem. 2004;112:223–8.PubMedView ArticleGoogle Scholar
  15. Gemmati D, Serino ML, Ongaro A, Tognazzo S, Moratelli S, Resca R, et al. A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol. 2001;67:183–8.PubMedView ArticleGoogle Scholar
  16. Isotalo PA, Wells GA, Donnelly JG. Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. Am J Hum Genet. 2000;67:986–90.PubMedPubMed CentralView ArticleGoogle Scholar
  17. Zetterberg H, Regland B, Palmer M, Ricksten A, Palmqvist L, Rymo L, et al. Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet. 2002;10:113–8.PubMedView ArticleGoogle Scholar
  18. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost. 2004;91:861–72.PubMedGoogle Scholar
  19. Ndrepepa G, Braun S, King L, Fusaro M, Keta D, Cassese S, et al. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2013;111:804–10.PubMedView ArticleGoogle Scholar
  20. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation. 2001;104:3063–8.PubMedView ArticleGoogle Scholar
  21. Jood K, Ladenvall P, Tjarnlund-Wolf A, Ladenvall C, Andersson M, Nilsson S, et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke. 2005;36:2077–81.PubMedView ArticleGoogle Scholar
  22. Rallidis LS, Gialeraki A, Fountoulaki K, Politou M, Sourides V, Travlou A, et al. G-455A polymorphism of beta-fibrinogen gene and the risk of premature myocardial infarction in Greece. Thromb Res. 2010;125:34–7.PubMedView ArticleGoogle Scholar
  23. Ghosh K, Kulkarni B, Nair S, Shetty S, Mohanty D. Human platelet alloantigen polymorphism in Glanzmann’sthrombasthenia and its impact on the severity of the disease. Br J Haematol. 2002;119:348–53.PubMedView ArticleGoogle Scholar
  24. Loncar R, Stoldt V, Hellmig S, Zotz RB, Mihalj M, Scharf RE. HPA-1 polymorphism of αIIbβ3 modulates platelet adhesion onto immobilized fibrinogen in an in-vitro flow system. Thromb J. 2007;5:2.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Kutluturk I, Karagöz A, Bezgin T, Oduncu V, Elveran A, Doğan C, et al. Relationship between angiotensin I-converting enzyme insertion/deletion gene polymorphism and retinal vein occlusion. Thromb J. 2014;12:17.PubMedPubMed CentralView ArticleGoogle Scholar
  26. Farrokhi E, Shayesteh F, Asadi Mobarakeh S, Roghani Dehkordi F, Ghatreh Samani K, Hashemzadeh CM. Molecular characterization of Iranian patients with possible familial hypercholesterolemia. Indian J Clin Biochem. 2011;26:244–8.PubMedPubMed CentralView ArticleGoogle Scholar
  27. Zhang M-d G, Gu W, Qiao S-b, Zhu E-j, Zhao Q-m, Lv SZ. Apolipoprotein E gene polymorphism and risk for coronary heart disease in the Chinese population: a meta-analysis of 61 studies including 6634 cases and 6393 controls. PLoS One. 2014;9:e95463.PubMedPubMed CentralView ArticleGoogle Scholar
  28. Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients. Acta Cardiol. 2011;66:483–8.PubMedGoogle Scholar
  29. Saghafi H, Mahmoodi MJ, Fakhrzadeh H, Heshmat R, Shafaee A, Larijani B. Cardiovascular risk factors in first-degree relatives of patients with premature coronary artery disease. Acta Cardiol. 2006;61(6):607–13.PubMedView ArticleGoogle Scholar
  30. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.PubMedView ArticleGoogle Scholar
  31. Sheridan SL, Viera AJ, Krantz MJ, Ice CL, Steinman LE, Peters KE, et al. The effect of giving global coronary risk information to adults: a systematic review. Arch Intern Med. 2010;170:230–9.PubMedView ArticleGoogle Scholar
  32. Janssens ACJ, Ioannidis JP, van Duijn CM, Little J, Khoury MJ. Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. Genome Med. 2011;3:16.PubMedPubMed CentralView ArticleGoogle Scholar
  33. Schussler JM. Effectiveness and safety of transradial artery access for cardiac catheterization. Proc (Bayl Univ Med Cent). 2011;24:205–9.Google Scholar
  34. Saha T, Khalequzzaman M, Akanda A-k, Saha S, Tushar AZ, Ahmed R, et al. Association of GRACE risk score with angiographic severity of coronary artery disease in patients with ST elevation myocardial infarction. Cardiovasc J. 2015;8:30–4.View ArticleGoogle Scholar
  35. Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47:65–71.PubMedView ArticleGoogle Scholar
  36. Gökdeniz T, Kalaycıoğlu E, Aykan AÇ, Boyacı F, Turan T, Gü İ, et al. Value of coronary artery calcium score to predict severity or complexity of coronary artery disease. Arq Bras Cardiol. 2014;102:120–7.PubMedPubMed CentralGoogle Scholar
  37. Khandelwal G, Jain A, Rathore M. Prediction of angiographic extent of coronary artery disease on the basis of clinical risk scores in patients of unstable angina. J Clin Diagn Res. 2015;9:OC13–6.PubMedPubMed CentralGoogle Scholar
  38. Özdemir B, Emül A, Özdemir L, Sağ S, Biçer M, Aydınlar A. Association of aortic diameters with coronary artery disease severity and albumin excretion. Biomed Res Int. 2015;2015:857628.PubMedPubMed CentralView ArticleGoogle Scholar
  39. Onaka L. Lipids. In: Anderson SC, Cockayne S, editors. Clinical chemistry: concepts and applications. London: WB Saunders; 1993. p. 166–83.Google Scholar
  40. Kotze MJ, Kriegshäuser G, Thiart R, de Villiers NJ, Scholtz CL, Kury F, et al. Simultaneous detection of multiple familial hypercholesterolemia mutations facilitates an improved diagnostic service in South African patients at high risk of cardiovascular disease. Mol Diagn. 2003;7:169–74.PubMedView ArticleGoogle Scholar
  41. Strip assay evaluator Web-edition, Release 2 (version 2.10). http://viennalab.sci-design.at/webevaluator/. Accessed 14 Oct 2016.
  42. Online Encyclopedia for Genetic Epidemiology studies (OEGE). Hardy-Weinberg equilibrium calculator including analysis for ascertainment bias. http://www.oege.org/software/hardy-weinberg.html. Accessed 14 Oct 2016.
  43. Fawzy MS, Hussein MH, Abdelaziz EZ, Yamany HA, Ismail HM, Toraih EA. Association of MicroRNA-196a2 variant with response to short-acting β2-agonist in COPD: an Egyptian pilot study. PLoS One. 2016;11:e0152834.PubMedPubMed CentralView ArticleGoogle Scholar
  44. McCune B, Mefford MJPC-ORD. Multivariate analysis of ecological data, version 5.0 for windows. 2006.Google Scholar
  45. Roberts R, Stewart AF, Wells GA, Williams KA, Kavaslar N, McPherson R. Identifying genes for coronary artery disease: an idea whose time has come. Can J Cardiol. 2007;23:7A–15A.PubMedPubMed CentralView ArticleGoogle Scholar
  46. Shaker O, Fayez S, Zarouk W, Shehata M. Fibrinogen b-455 G/A and prothrombin 20210 G/A polymorphisms and coronary heart disease: an Egyptian case–control study. Med Rese J. 2011;10:102–9.View ArticleGoogle Scholar
  47. Dai X, Wiernek S, Evans JP, Runge MS. Genetics of coronary artery disease and myocardial infarction. World J Cardiol. 2016;8:1–23.PubMedPubMed CentralView ArticleGoogle Scholar
  48. Butt C, Zheng H, Randell E, Robb D, Parfrey P. Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. Blood. 2003;101:3037–41.PubMedView ArticleGoogle Scholar
  49. Zaatari GS, Otrock ZK, Sabbagh AS, Mahfouz RA. Prevalence of factor V R2 (H1299R) polymorphism in the Lebanese population. Pathology. 2006;38:442–4.PubMedView ArticleGoogle Scholar
  50. Segers K, Dahlbäck B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost. 2007;98:530–42.PubMedGoogle Scholar
  51. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost. 2001;86:395–403.PubMedGoogle Scholar
  52. Trifonova EA, Spiridonova MG, Stepanov VA. Genetic diversity and the structure of linkage disequilibrium in the methylenetetrahydrofolate reductase locus. Genetika. 2008;44:1410–9.PubMedGoogle Scholar
  53. Tajouri L, Martin V, Gasparini C, Ovcaric M, Curtain R, Lea RA, et al. Genetic investigation of methylenetetrahydrofolate reductase (MTHFR) and catechol-O-methyl transferase (COMT) in multiple sclerosis. Brain Res Bull. 2006;69:327–31.PubMedView ArticleGoogle Scholar
  54. Heidari MM, Khatami M, Hadadzadeh M, Kazemi M, Mahamed S, Malekzadeh P, et al. Polymorphisms in NOS3, MTHFR APOB and TNF-α Genes and Risk of Coronary Atherosclerotic Lesions in Iranian Patients. Res Cardiovasc Med. 2015;5:e29134.PubMedPubMed CentralView ArticleGoogle Scholar
  55. Almawi WY, Ameen G, Tamim H, Finan RR, Irani-Hakime N. Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR]) C677T gene polymorphism in angiographically documented coronary artery disease. J Thromb Thrombolysis. 2004;17:199–205.PubMedView ArticleGoogle Scholar
  56. Neto AI, Moura Jr JR, Persuhn DC. Frequency of MTHFR G1793A polymorphism in individuals with early coronary artery disease: cross-sectional study. Sao Paulo Med J. 2013;131:296–300.PubMedView ArticleGoogle Scholar
  57. Yamada Y, Matsuo H, Segawa T, Watanabe S, Kato K, Hibino T, et al. Assessment of genetic risk for myocardial infarction. Thromb Haemost. 2006;96:220–7.PubMedGoogle Scholar
  58. Schürks M, Zee RY, Buring JE, Kurth T. Interrelationships among the MTHFR 677C > T polymorphism, migraine, and cardiovascular disease. Neurology. 2008;71:505–13.PubMedPubMed CentralView ArticleGoogle Scholar
  59. Hsu LA, Ko YL, Wang SM, Chang CJ, Hsu TS, Chiang CW, et al. The C677T mutation of the methylene tetrahydrofolate reductase gene is not associated with the risk of coronary artery disease or venous thrombosis among Chinese in Taiwan. Hum Hered. 2001;51:41–5.PubMedView ArticleGoogle Scholar
  60. Yilmaz H, Agachan B, Ergen A, Karaalib ZE, Isbir T. Methylene tetrahydrofolate reductase C677T mutation and left ventricular hypertrophy in Turkish patients with type II diabetes mellitus. J Biochem Mol Biol. 2004;37:234–8.PubMedGoogle Scholar
  61. Caner M, Bircan R, Sevinç D, Benli F, Güney AI, Kurtoglu N. MTHFR, prothrombin and Factor V gene variants in Turkish patients with coronary artery stenosis. Genet Mol Biol. 2008;31:836–8.View ArticleGoogle Scholar
  62. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator plasmin systems in angiogenesis. Arterioscler Thromb Va-sc Biol. 2001;21:1104–17.View ArticleGoogle Scholar
  63. Mehta R, Shapiro A. Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 2008;14:1255–60.PubMedView ArticleGoogle Scholar
  64. Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, et al. Acute release of plasminogen activator inhibitor-1 in ST segment elevation myocardial infarction predicts mortality. Circulation. 2003;108:391–4.PubMedView ArticleGoogle Scholar
  65. Ding J, Nicklas BJ, Fallin MD, de Rekeneire N, Kritchevsky SB, Pahor M, et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J. 2006;152:1109–15.PubMedView ArticleGoogle Scholar
  66. Li Y, Di C, Li W, Cai W, Tan X, Xu L, et al. Oncomirs miRNA-221/222 and tumor suppressors miRNA-199a/195 Are crucial miRNAs in liver cancer: a systematic analysis. Dig Dis Sci. 2016;61:2315–27.PubMedPubMed CentralView ArticleGoogle Scholar
  67. Zhang H, Dong P, Yang X, Liu Z. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis. Int J Clin Exp Med. 2014;7:3777–88.PubMedPubMed CentralGoogle Scholar
  68. Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G gene polymorphism on the thrombotic risk. Thromb Res. 2008;122:736–42.PubMedView ArticleGoogle Scholar
  69. Ismail S, Abdel Azeem AA, Abdel Hamid MA, Nowier SR, Morad H. The role of 4G/5G genetic polymorphism of plasminogen activator inhibitor-1 gene in myocardial infarction among Egyptians. Life Sci J. 2011;8:32–9.Google Scholar
  70. Anderson JL, Muhlestein JB, Habashi J, Carlquist JF, Bair TL, Elmer SP, et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol. 1999;34:1778–83.PubMedView ArticleGoogle Scholar
  71. Crainich P, Jenny NS, Tang Z, Arnold AM, Kuller LH, Manolio T, et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost. 2003;1:1799–804.PubMedView ArticleGoogle Scholar
  72. Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond). 2006;30:1308–14.View ArticleGoogle Scholar
  73. Alessi M-C, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol. 2007;18:240–5.PubMedView ArticleGoogle Scholar
  74. Fernandes KS, Sandrim VC. 4G/5G polymorphism modulates PAI-1 circulating levels in obese women. Mol Cell Biochem. 2012;364:299–301.PubMedView ArticleGoogle Scholar
  75. Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, Grandone E, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18:152–6.PubMedView ArticleGoogle Scholar
  76. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991;11:183–90.PubMedView ArticleGoogle Scholar
  77. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost. 1995;74:837–41.PubMedGoogle Scholar
  78. Nordt TK, Lohrmann J, Bode C. Regulation of PAI-1 expression by genetic polymorphism. Impact on atherogenesis. Thromb Res. 2001;103:S1–5.PubMedView ArticleGoogle Scholar
  79. Eliasson M, Asplund K, Ervin PE, Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin: the Northern Sweden MONICA study. Atherosclerosis. 1995;113:41–53.PubMedView ArticleGoogle Scholar
  80. Floyd CN, Ferro A, Warner TD. Expression of the PlA2 allele of glycoprotein IIIa and its impact on platelet function. JRSM Cardiovasc Dis. 2015;4:2048004015610252.PubMedPubMed CentralGoogle Scholar
  81. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest. 1989;83:1778–81.PubMedPubMed CentralView ArticleGoogle Scholar
  82. Corral J, González-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V. HPA-1 genotype in arterial thrombosis-role of HPA-1b polymorphism in platelet function. Blood Coagul Fibrinolysis. 1997;8:284–90.PubMedView ArticleGoogle Scholar
  83. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090–4.PubMedView ArticleGoogle Scholar
  84. Abboud N, Amin H, Ghazouani L, Ben Haj Khalifa S, Ben Khalafallah A, Aded F, Almawi WY, Mahjoub T. Polymorphisms of human platelet alloantigens HPA-1 and HPA-2 associated with severe coronary artery disease. Cardiovasc Pathol. 2010;19:302–7.PubMedView ArticleGoogle Scholar
  85. Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, et al. Effect of the Pl (A2) alloantigen on the function of beta (3)-integrins in platelets. Blood. 2001;97:3093–9.PubMedView ArticleGoogle Scholar
  86. Floyd CN, Mustafa A, Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis. PLoS One. 2014;9:e101518.PubMedPubMed CentralView ArticleGoogle Scholar
  87. Floyd CN, Ellis BH, Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for stroke: a systematic review and meta-analysis. PLoS One. 2014;9:e100239.PubMedPubMed CentralView ArticleGoogle Scholar
  88. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195–8.PubMedPubMed CentralView ArticleGoogle Scholar
  89. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke and venous thrombosis in a large cohort of US men. Circulation. 1999;99:999–1004.PubMedView ArticleGoogle Scholar
  90. Samani NJ, Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res. 1997;33:693–7.PubMedView ArticleGoogle Scholar
  91. Scaglione L, Bergerone S, Gaschino G, Imazio M, Maccagnani A, Gambino R, et al. Lack of relationship between the P1A1/P1A2 polymorphism of platelet glycoprotein IIIa and premature myocardial infarction. Eur J Clin Invest. 1998;28:385–8.PubMedView ArticleGoogle Scholar
  92. Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost. 2001;85:626–33.PubMedGoogle Scholar
  93. Zotz RB, Winkelmann BR, Mu¨ller C, Boehm BO, Ma¨rz W, Scharf RE. Association of polymorphisms of platelet membrane integrins αIIbβ3 (HPA-1b/PlA2) and α2β12807TT) with premature myocardial infarction. J Thromb Haemost. 2005;3:1522–9.PubMedView ArticleGoogle Scholar
  94. Zeinali N, Hashemi M, Mirmohammadsadeghi M, Mirmohammadsadeghi H, Eskandari N, Sabzghabaee AM. Association of angiotensin-converting enzyme genotype, insertion/deletion polymorphism and saphenous vein graft atherosclerosis in Iranian patients. Braz J Cardiovasc Surg. 2015;30:557–61.PubMedPubMed CentralGoogle Scholar
  95. Demurtas P, Orrù G, Coni P, Minerba L, Corrias M, Sirigu P, et al. Association between the ACE insertion/deletion polymorphism and pterygium in Sardinian patients: a population based case–control study. BMJ Open. 2014;4:e005627.PubMedPubMed CentralView ArticleGoogle Scholar
  96. Cambien F, Poirer O, Lecerf L, Evans A, Cambou J-P, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641–4.PubMedView ArticleGoogle Scholar
  97. Morris BJ. Hypothesis: an angiotensin converting enzyme genotype present in one in three Caucasians, is associated with increased mortality rate. Clin Exp Pharmacol Physiol. 1996;23:1–10.PubMedView ArticleGoogle Scholar
  98. Oike Y, Hata A, Ogata Y, Numata Y, Shido K, Kondo K. Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm: implication in the pathogenesis of myocardial infarction. J Clin Invest. 1995;96:2975–9.PubMedPubMed CentralView ArticleGoogle Scholar
  99. Ohishi M, Fujii K, Minamino T, Hagaki J, Kamitani A, Rakugi H, et al. A potent genetic risk factor for restenosis. (Letter). Nature Genet. 1993;5:324–5.PubMedView ArticleGoogle Scholar
  100. Samani NJ, Thompson JR, O’Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 1996;94:708–12.PubMedView ArticleGoogle Scholar
  101. Zhou L, Xi B, Wei Y, Shen W, Li Y. Meta-analysis of the association between the insertion/deletion polymorphism in ACE gene and coronary heart disease among the Chinese population. J Renin Angiotensin Aldosterone Syst. 2012;13:296–304.PubMedView ArticleGoogle Scholar
  102. Higaki J, Baba S, Katsuya T, Sato N, Ishikawa K, Mannami T, et al. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: the Suita Study. Circulation. 2000;101:2060–5.PubMedView ArticleGoogle Scholar
  103. Butler R, Morris AD, Struthers AD. Angiotensin-converting enzyme gene polymorphism and cardiovascular disease. Clin Sci. 1997;93:391–400.PubMedView ArticleGoogle Scholar
  104. Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular genetics of familial hypertrophic cardiomyopathy (FHC). J Hum Genet. 2003;48:55–64.PubMedView ArticleGoogle Scholar
  105. Tseng CH, Tseng FH, Chong CK, Tseng CP, Cheng JC. Angiotensin-converting enzyme genotype and peripheral arterial disease in diabetic patients. Exp Diabetes Res. 2012;2012:698695.PubMedGoogle Scholar
  106. Zhang Z, Xu G, Liu D, Fan X, Zhu W, Liu X. Angiotensin-converting enzyme insertion/deletion polymorphism contributes to ischemic stroke risk: a meta-analysis of 50 case-control studies. PLoS One. 2012;7:e46495.PubMedPubMed CentralView ArticleGoogle Scholar
  107. Fatini C, Gensini F, Sticchi E, Battaglini B, Prisco D, Fedi S, et al. ACE DD genotype: an independent predisposition factor to venous thromboembolism. Eur J Clin Invest. 2003;33:642–7.PubMedView ArticleGoogle Scholar
  108. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. New Eng J Med. 1995;332:706–11.PubMedView ArticleGoogle Scholar
  109. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78:539–52.PubMedPubMed CentralView ArticleGoogle Scholar
  110. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–6.PubMedPubMed CentralView ArticleGoogle Scholar
  111. Suehiro T, Morita T, Inoue M, Kumon Y, Ikeda Y, Hashimoto K. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet. 2004;115:91–6.PubMedView ArticleGoogle Scholar
  112. Shen H, Damcott CM, Rampersaud E, Pollin TI, Horenstein RB, McArdle PF, et al. Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish. Arch Intern Med. 2010;170:1850–5.PubMedPubMed CentralView ArticleGoogle Scholar
  113. Tybjaerg-Hansen A, Humphries SE. Familial defective apolipoprotein B-100: A single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis. 1992;96:91–107.PubMedView ArticleGoogle Scholar
  114. Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med. 1998;338:1577–84.PubMedView ArticleGoogle Scholar
  115. Ludwig EH, Hopkins PN, Allen A, Wu LL, Williams RR, Anderson JL, et al. Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins. J Lipid Res. 1997;38:1361–73.PubMedGoogle Scholar
  116. Borén J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest. 1998;101:1084–93.PubMedPubMed CentralView ArticleGoogle Scholar
  117. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160:407–20.PubMedView ArticleGoogle Scholar
  118. Sabbagh AS, Daher RT, Otrock ZK, Khalek RN, Zaatari GS, Mahfouz RA. ApoB-100 R3500Q mutation in the Lebanese population: prevalence and historical review of the literature. Mol Biol Rep. 2007;34:267–70.PubMedView ArticleGoogle Scholar
  119. Zakharova FM, Damgaard D, Mandelshtam MY, Golubkov VI, Nissen PH, Nilsen GG, et al. Familial hypercholesterolemia in St-Petersburg: the known and novel mutations found in the low density lipoprotein receptor gene in Russia. BMC Med Genet. 2005;6:6.PubMedPubMed CentralView ArticleGoogle Scholar
  120. Sözen MM, Whittall R, Oner C, Tokatli A, Kalkanoğlu HS, Dursun A, et al. The molecular basis of familial hypercholesterolaemia in Turkish patients. Atherosclerosis. 2005;180:63–71.PubMedView ArticleGoogle Scholar
  121. Wang YL, Sun LM, Zhang L, Xu HT, Dong Z, Wang LQ, et al. Association between apolipoprotein E polymorphism and myocardial infarction risk: a systematic review and meta-analysis. FEBS Open Bio. 2015;5:852–8.PubMedPubMed CentralView ArticleGoogle Scholar
  122. Ghebranious N, Ivacic L, Mallum J, Dokken C. Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology. Nucleic Acids Res. 2005;33:e149.PubMedPubMed CentralView ArticleGoogle Scholar
  123. McNeill E, Channon KM, Greaves DR. Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications. Clin Sci. 2010;118:641–55.PubMedView ArticleGoogle Scholar
  124. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol. 1993;71:160–5.PubMedView ArticleGoogle Scholar
  125. Ventakaramana P, Reddy C, Ferrell RE. Apolipoprotein E polymorphism in two populations of Andhra Pradesh. Ind J Hum Genet. 1999;5:31–5.Google Scholar
  126. Hergenc G, Taga Y, Emerk K, Cirakoglu B. Apolipoprotein E genotyping in Turkish myocardial infarction survivors and healthy controls. J Biomed Sci. 1995;2:46–9.PubMedView ArticleGoogle Scholar
  127. Dzimiri N, Meyer BF, Hussain SS, Basco C, Afrane B, Halees Z. Relevance of apolipoprotein E polymorphism for coronary artery disease in the Saudi population. Arch Pathol Lab Med. 1999;123:1241–5.PubMedGoogle Scholar
  128. Lenzen HJ, Assmann G, Buchwalsky R, Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem. 1986;32:778–81.PubMedGoogle Scholar
  129. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622–30.PubMedView ArticleGoogle Scholar
  130. McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology. 1999;53:1308–11.PubMedView ArticleGoogle Scholar
  131. Liu S, Song Y, Hu FB, Niu T, Ma J, Gaziano M, Stampfer MJ. A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men. Atherosclerosis. 2004;177:119–26.PubMedView ArticleGoogle Scholar
  132. Xu H, Li H, Liu J, Zhu D, Wang Z, Chen A, Zhao Q. Meta-analysis of apolipoprotein E gene polymorphism and susceptibility of myocardial infarction. PLoS One. 2014;9:e104608.PubMedPubMed CentralView ArticleGoogle Scholar
  133. Zhang Y, Tang HQ, Peng WJ, Zhang BB, Liu M. Meta-analysis for the Association of Apolipoprotein E ε2/ε3/ε4 Polymorphism with Coronary Heart Disease. Chin Med J (Engl). 2015;128:1391–8.View ArticleGoogle Scholar
  134. Mahley RW, Rall Jr SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507–37.PubMedView ArticleGoogle Scholar
  135. Jiang L, Zhong J, Dou X, Cheng C, Huang Z, Sun X. Effects of ApoE on intracellular calcium levels and apoptosis of neurons after mechanical injury”. Neuroscience. 2015;301:375–83.PubMedView ArticleGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement